Mechanistic basis for impaired B cell depletion after anti-CD20 treatment of African American with neuro-inflammatory disorders

Go Back to All Clinical Trials

Mechanistic basis for impaired B cell depletion after anti-CD20 treatment of African American with neuro-inflammatory disorders

Brief description of study

The purpose of this research is to better understand why African Americans with Multiple Sclerosis (MS), Neuromyelitis optica (NMO), or other neuroinflammatory disorders, have fast B-cell repopulation after receiving anti-CD20 therapies such as Rituximab and Ocrelizumab. The researchers plan to collect up to 30.5 mL (2.1 tbsp) of blood sample for each subject at a single time-point during the bi-annual clinic visit that is immediately prior to scheduled aCD20 infusion. For each subject, per our standard of care the researchers plan to collect routine clinical studies as well as the research labs. Blood samples will be analyzed at NYU specialty laboratories according to the appropriate workflow as specified in the Lab Manual.

Clinical Study Identifier: s22-00483

Principal Investigator: Ilya Kister.

Other Investigators: Carrie Lyn Sammarco, Arnaldo A Arbini, Michelle Krogsgaard, Vito Pasquale Arena, Tyler Ellis Smith, Gregg Silverman, David Fenyo, Jonathan E Howard, Jennifer K Abate, Robert W Charlson, Lauren B. Krupp.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies